G
Grace Therapeutics, Inc. (GRCE)
4.67
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
4.67
0.00 (0.00%)
No Data
Ushbu aksiya uchun yangiliklar yo'q.
| KO‘RSATKICH NOMI | KO‘RSATKICH | SANOAT O‘RTACHASI | 5 YILLIK TREND | BALL |
|---|---|---|---|---|
| Joriy likvidlik ko'rsatkichi | 14.96 | 6.05 | 10 | |
| Tezkor likvidlik nisbati | 14.96 | 5.63 | 10 | |
| Qarz/Kapital nisbati | 0.00 | 0.30 | 10 | |
| Qarz/Aktivlar nisbati | 0.00 | 1.04 | 10 | |
| Foiz to‘lov qoplami | N/A | -16.91 | 1.0 | |
| O‘rtacha ball | 8.2 | |||
| KO‘RSATKICH | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Jami daromad | N/A | N/A | N/A | N/A | N/A |
| Yalpi foyda | N/A | -124K | -11K | -7K | -7K |
| Operatsion daromad | -16M | -18M | -11M | -17M | -11M |
| Sof foyda | -10M | -42M | -13M | -10M | -6M |
| EBITDA | -16M | -18M | -11M | -17M | -11M |
| Nomi | DAROMAD O'SISHI | EPS O‘SISHI | BALL |
|---|---|---|---|
| Joriy chorak | N/A | -322.73 | 1.0 |
| Keyingi chorak | N/A | 19.05 | 5.0 |
| Joriy yil | N/A | -6.33 | 1.0 |
| Keyingi yil | N/A | 23.21 | 5.5 |
| O‘rtacha ball | 3.1 | ||
| NOMI | DAROMAD | SOF FOYDA | EPS | FCF | BALL |
|---|---|---|---|---|---|
| Chorak/Chorak | 999 | -146.79 | -133.32 | 31.26 | 5.5 |
| Yil/Yil | 999 | 44.28 | 61.11 | 44.35 | 10 |
| 3 yil o‘rtacha | 999 | -78.93 | -44.67 | 3.13 | 4.0 |
| 5 yil o‘rtacha | 779.2 | -32.76 | -2.1 | 5.55 | 4.3 |
| O‘rtacha ball | 6.0 | ||||
| NOMI | JORIY | SANOAT | BALL |
|---|---|---|---|
| Dividend foizi | 0.00 | N/A | 1.0 |
| To'lov koeffitsienti | 0.00 | N/A | 1.0 |
| 5 yillik dividend o‘sishi | N/A | N/A | 1.0 |
| Dividend oshgan yillar | N/A | N/A | 1.0 |
| O‘rtacha ball | 1.0 | ||
| NOMI | MASSHTAB | BALL |
|---|---|---|
| Bozor ulushi | Yo'q | 1.0 |
| Nomoddiy aktivlar | Yo'q | 1.0 |
| O'zgartirish xarajatlari | Yo'q | 1.0 |
| Tarmoq ta'siri | Yo'q | 1.0 |
| Masshtab ta'siri | Yo'q | 1.0 |
| O‘rtacha ball | 1.0 | |
Naqd pul zahiralari $18.7M kelgusi qarz to'lovlarini $0.0 zo'rg'a qoplaydi
Jami joriy aktivlar $19.2M jami joriy majburiyatlardan $1.3M ko'p bo'lib, ajoyib likvidlikni ta'kidlaydi
Qarz/kapital nisbati (0.0) tarmoq o'rtachasiga yaqin bo'lib, muvozanatli leverajni aks ettiradi
Foiz xarajatlari mavjud, ammo EBIT ma'lumotlari mavjud emas, bu potentsial rentabellik muammolarini ko'rsatadi
Salbiy erkin pul oqimi -$2.2M kompaniyaning qayta investitsiya qilish yoki qarzni to'lash qobiliyatini cheklaydi